市場調査レポート

肝臓癌治療薬

Liver Cancer Drugs

発行 Global Industry Analysts, Inc. 商品コード 121152
出版日 ページ情報 英文 506 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
肝臓癌治療薬 Liver Cancer Drugs
出版日: 2010年04月01日 ページ情報: 英文 506 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界の肝臓癌治療薬市場について分析し、肝臓癌の概要とリスクファクター、診断、治療法とともに、Nexavarの認可と今後上市予定の薬剤をまとめ、市場に参入する企業のプロファイルを交え、概略以下の構成でお届けします。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 市場概要と動向
    • 現在のシナリオと見通し
    • アジアが肝臓癌罹患率でリード
    • 肝臓癌の疫学と病因の格差
    • 米国で増加する肝臓癌患者数
    • 日本で減少するHCC
    • 従来の治療法
    • 標的療法には多くのターゲット人口が存在
    • Nexavar:肝臓癌で唯一認可された標的療法
    • ThemoDoxが2011年に上市予定
    • 肝臓癌治療:研究成果の向上に魅力
    • 併用薬剤が影響
    • 肝臓癌治療におけるパイプライン薬剤
    • パイプライン薬剤概要
  • 疾患概要
    • 肝臓:重要な臓器
    • 肝臓の機能
    • 肝臓癌の概要
    • 肝臓癌の種類
    • リスクファクター
    • 肝臓癌の兆候
    • 肝臓癌検出検査
    • 肝臓癌の診断
    • 肝臓癌の予後診断
    • 肝臓癌の治療
  • Nexavarの認可
  • 近年の業界活動
  • 主要参入企業
    • 4SC AG
    • Actavis Group, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • ArQule, Inc.
    • Bayer Schering Pharma AG
    • Bristol-Myers Squibb Company
    • Celsion Corp.
    • Eli Lilly & Company
    • ImClone Systems Inc.
    • F. Hoffmann?La Roche Ltd.
    • Jennerex Biotherapeutics, Inc.
    • Onyx Pharmaceuticals, Inc.
    • Pfizer Inc
    • Progen Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
  • 世界市場見通し

第3章 競合環境

  • 企業プロファイル:50社(部署/子会社含め54社)
    • 米国
    • カナダ
    • 日本
    • 欧州
    • アジア太平洋諸国(日本を除く)
    • 中東
目次
Product Code: MCP-6297

Abstract

This report analyzes the Global market for Liver Cancer Drugs in US$ Million. Annual estimates and forecasts are provided for the period 2007 through 2015. The report profiles 40 companies including 4SC AG, Actavis Group, Inc., Alnylam Pharmaceuticals, Inc., ArQule, Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Celsion Corp, Eli Lilly & Company, ImClone Systems Inc., F. Hoffmann-La Roche Ltd., Jennerex Biotherapeutics, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW & DYNAMICS

  • Current Scenario and Outlook
  • Asians Lead in Liver Cancer Prevalence and Incidence
  • Table 1: Incidence and Mortality of Liver Cancer in Select Countries: 2007 (includes corresponding Graph/Chart)
  • Disparity in Epidemiology and Etiology Of Liver Cancer
  • Liver Cancer Incidence Rising in the US
  • HCC Incidence Declines in Japan
  • Conventional Therapies Plagued with Lower Penetration
  • Therapies and Eligible Patient Population
  • Major Target Population Exists for Targeted Therapies
  • Nexavar - The Only Approved Targeted Therapy in Liver Cancer
  • Table 2: Global Nexavar Sales (2007-2015) (in US$ Million) (includes corresponding Graph/Chart)
  • Japanese Approval for Nexavar® in 2009
  • Nexavar Proves Efficacy in Asian Patients
  • Nexavar Ongoing Clinical Trials
  • Nexavar Being Evaluated As Adjuvant Therapy
  • Development of Nexavar Plus Tarceva Therapy Underway
  • Liver Cancer Treatment to Boost Nexavar' s Revenues
  • ThermoDox Likely to Enter Market in 2011
  • Table 3: Worldwide ThermoDox Sales: 2011-2015 (includes corresponding Graph/Chart)
  • Liver Cancer Therapy - Attracting Increasing Research Efforts
  • Combination Drugs to Make an Impact
  • Pipeline Drugs in Liver Cancer Treatment - A Snapshot
  • Select Pipeline Drugs in Phase III Clinical Trials for Liver Cancer Treatment
  • Select Pipeline Drugs in Phase II Clinical Trials for Liver Cancer Treatment
  • Select Pipeline Drugs in Other Clinical Trial Stages for Liver Cancer Treatment
  • Overview of Select Drugs In Pipeline
  • Sutent® (Pfizer)
  • ThermoDox + RFA (Celsion Corp.)
  • Sorafenib + TACE (Bayer)
  • Sorafenib + Tegafur/Uracil
  • Muparfostat (Formerly PI-88) (Progen Pharmaceuticals/ Global TransBiotech)
  • Avastin + Tarceva (Roche/Genentech)
  • NX-1207 (Nymox Pharmaceutical Corp.)
  • ALN-VSP (Alnylam Pharmaceuticals, Inc.)
  • AV-951 (Aveo Pharmaceuticals)
  • JX-594 (Jennerex)
  • Afinitor/RAD001 (Novartis)
  • 4SC-201 (4SC)
  • CTCE-9908 (Chemokine Therapeutics)
  • ARQ 197 (ArQule, Inc.)

2. DISEASE OVERVIEW

  • Liver - A Vital Organ
  • Functions of the Liver
  • Overview of Liver Cancer
  • Benign Liver Tumors
  • Types of Benign Liver Tumors
  • Hemangiomas
  • Hepatic Adenomas
  • Focal Nodular Hyperplasia
  • Malignant Liver Tumors
  • Types of Liver Cancer
  • Hepatocellular Carcinoma (HCC)
  • Cholangiocarcinomas
  • Hepatoblastoma
  • Hemangiosarcomas and Angiosarcomas
  • Hepatoblastoma
  • Secondary Liver Cancer or Metastatic Cancer
  • Risk Factors
  • Symptoms of Liver Cancer
  • Tests for Detection of Liver Cancer
  • Diagnosis of Liver Cancer
  • Blood Tests
  • Imaging Studies
  • Ultrasound
  • Computed Tomography
  • Magnetic Resource Imaging
  • Angiography
  • FDG-PET
  • Biopsy
  • Prognosis of Liver Cancer
  • Treatment Of Liver Cancer
  • Targeted Therapy
  • Working of Targeted Cancer Therapies
  • Development of Targeted Therapies
  • Effect of Targeted Therapies on the Treatment of Cancer
  • Chemotherapy
  • Surgery
  • Side Effects and Risks Associated with Surgery
  • Cryosurgery
  • Benefits of Cryosurgery
  • Limitations of Cryosurgery
  • Liver Transplant
  • Side effects and Risks Associated with Liver Transplantation
  • Tumor Embolization and Ablation
  • Radiation Therapy
  • Side-effects Associated with Radiation Therapy
  • Radiofrequency Ablation
  • Hepatic Artery Chemoembolization
  • A Focus on Hepatocellular Carcinoma
  • Epidemiology
  • Pathogenesis
  • Pathology
  • Prognosis and Staging
  • Treatment
  • Treatment Follow-up

3. NEXAVAR' S APPROVALS IN REGIONAL MARKETS

  • Bayer Secures Japanese Approval for Nexavar®
  • Bayer Obtains Approval for Nexavar in China
  • Bayer Obtains Approval for Marketing Nexavar® in Singapore
  • Bayer Receives Health Canada' s Approval for Nexavar
  • Bayer Obtains FDA Approval for Nexavar in Treating Liver Cancer
  • Bayer Receives EU Clearance for Marketing Nexavar

4. RECENT INDUSTRY ACTIVITY

  • NICE Refuses to Take Nexavar on National Health Service (NHS)
  • Delcath' s Doxorubicin Obtains Orphan-Drug Designation from FDA
  • CACMS Obtains Clearance for Traditional Chinese Medicine for Liver Cancer
  • Curetech Obtains FDA Approval to Commence Trial on CT-011
  • Bayer Mulls Over Legal Recourse to Avert Nexavar' Generic in India
  • Jennerex Generates Funds for Developing JX-594
  • Celsion to Extend ThermoDox Phase III Trial to Japan
  • Bayer Commences Phase III trials on Nexavar and Tarceva Combination Therapy
  • Tiandiren Pharma Begins Construction of Biotech Park
  • Can-Fite to Commence Phase I/II Trial of CF102
  • Celsion' s ThermoDox Obtains Orphan Drug Designation from FDA
  • Alnylam Obtains FDA Clearance to Commence Phase I Trial on ALN-VSP
  • ArQule Enrolls Patients for Phase II Study with ARQ 197 in Hepatocellular Carcinoma
  • PharmaSynth Licenses Muparfostat to Global TransBiotech
  • Bayer-Onyx Commences Clinical Trials on Nexavar as Adjuvant Therapy
  • Protherics Begins Phase II Clinical Trial on Prolarix
  • Chemokine Obtains Hong Kong DoH Clearance on CTCE-9908
  • AstraZeneca Forges New Alliance for Anti-Cancer Compounds
  • BioAlliance Annuls Trials on Transdrug® for Liver Cancer Treatment
  • Chemokine Obtains Health Canada Approval to Start CTCE-9908 Phase II Trial
  • Progen Pharmaceuticals Spins-Off its Manufacturing Business
  • Metabasis Obtains EMEA Orphan Drug Designation for Liver Cancer Drug
  • Metabasis Obtains FDA Orphan Drug Designation for Liver Cancer Drug

5. FOCUS ON SELECT GLOBAL PLAYERS

  • 4SC AG (Germany)
  • Actavis Group, Inc. (USA)
  • Alnylam Pharmaceuticals, Inc. (USA)
  • ArQule, Inc. (USA)
  • Bayer Schering Pharma AG (Germany)
  • Bristol-Myers Squibb Company (US)
  • Celsion Corp. (USA)
  • Eli Lilly & Company (US)
  • ImClone Systems Inc.
  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Jennerex Biotherapeutics, Inc. (USA)
    • Onyx Pharmaceuticals, Inc. (USA)
    • Pfizer Inc. (USA)
    • Progen Pharmaceuticals Ltd. (Australia)
    • Teva Pharmaceutical Industries Ltd. (Israel)

6. GLOBAL MARKET PERSPECTIVE

  • Table 4: World Recent Past, Current & Future Analysis for Liver Cancer Drugs Market Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Back to Top